Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
REM Sleep Behavior Disorder01:15

REM Sleep Behavior Disorder

REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Introducing a gatekeeping system for amyloid status assessment in mild cognitive impairment.

European journal of nuclear medicine and molecular imaging·2022
Same author

Mapping social reward and punishment processing in the human brain: A voxel-based meta-analysis of neuroimaging findings using the social incentive delay task.

Neuroscience and biobehavioral reviews·2021
Same author

Argyrophilic grain disease in individuals younger than 75 years: clinical variability in an under-recognized limbic tauopathy.

European journal of neurology·2020
Same author

[Tauopathies : From molecule to therapy].

Der Nervenarzt·2018
Same author

[Hemichorea with Contralateral High Signal Intensity Putaminal Lesion on T1-Weighted Images in Non-Ketotic Hyperglycemia].

Fortschritte der Neurologie-Psychiatrie·2016
Same author

Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program.

Parkinsonism & related disorders·2015

Related Experiment Video

Updated: May 19, 2026

Marble Burying and Nestlet Shredding as Tests of Repetitive, Compulsive-like Behaviors in Mice
06:50

Marble Burying and Nestlet Shredding as Tests of Repetitive, Compulsive-like Behaviors in Mice

Published on: December 24, 2013

[Repetitive impulse-associated behavioral disorders in Parkinson's disease].

R Katzenschlager1, K S Goerlich, T van Eimeren

  • 1Neurologische Abteilung, Donauspital/SMZ-Ost, Wien, Österreich.

Der Nervenarzt
|August 11, 2012
PubMed
Summary

Parkinson's disease (PD) patients frequently experience behavioral disorders like impulse control disorders (ICDs) and dopamine dysregulation syndrome (DDS). Dopamine agonist treatment is a key risk factor, necessitating careful management strategies.

More Related Videos

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents
08:38

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents

Published on: September 1, 2011

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Related Experiment Videos

Last Updated: May 19, 2026

Marble Burying and Nestlet Shredding as Tests of Repetitive, Compulsive-like Behaviors in Mice
06:50

Marble Burying and Nestlet Shredding as Tests of Repetitive, Compulsive-like Behaviors in Mice

Published on: December 24, 2013

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents
08:38

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents

Published on: September 1, 2011

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Area of Science:

  • Neuroscience
  • Psychiatry
  • Movement Disorders

Context:

  • Parkinson's disease (PD) is frequently accompanied by behavioral disorders.
  • Impulse control disorders (ICDs) affect 13-14% of PD patients, including pathological gambling, binge eating, compulsive shopping, and hypersexuality.
  • Dopamine dysregulation syndrome (DDS) and punding are other significant behavioral issues in PD patients.

Purpose:

  • To review the behavioral disorders associated with Parkinson's disease.
  • To identify treatment-related and shared risk factors for these disorders.
  • To discuss the underlying neuronal mechanisms and current management strategies.

Summary:

  • Key risk factors include dopamine agonists for ICDs and high dopaminergic doses for DDS and punding.
  • Shared risk factors encompass young age, impulsive traits, depression, and potentially dyskinesia.
  • Neuronal changes in the reward system and orbitofrontal cortex are implicated.
  • Current management for ICDs involves reducing or discontinuing dopamine agonists, though evidence is limited.

Impact:

  • Highlights the significant impact of behavioral disorders on PD patients' quality of life.
  • Identifies critical risk factors associated with dopaminergic therapies.
  • Underscores the need for further research into effective management strategies for these challenging conditions.